Q4 FY2026 EarningsFY26 Q4 results missed consensus on the top and bottom lines, though gross margins remained stable. Revenue of $4.22M was slightly below the $4.29M expected, while GAAP EPS loss of -$8.44 significantly widened compared to the -$3.42 consensus due to massive share dilution and higher-than-expected operating expenses. Despite strong cartridge sales growth (+41% YoY), the company continues to consume cash rapidly, reporting -$11.9M in cash from operations vs. -$10.25M expected, and has received a going concern warning.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Intelligent Bio Solutions(INBS) the Revenue is 1.146 M (--%), Miss estimate;the EBIT is -3.969 M (--%), Miss estimate;the EPS is -0.9 (--%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B--
0.00B--
-0.00B--%
EBITMiss expectations
-0.00B--
-0.00B--
-0.00B--%
EPSExceed expectations
-0.9--
-1.58--
+0.6800--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf